Effects of race on lipid-lowering management in hospitalized patients with coronary heart disease

被引:4
|
作者
Dressler, DD
Jacobson, TA
机构
[1] Emory Univ, Sch Med, Dept Med, Div Gen Med, Atlanta, GA 30303 USA
[2] Hosp Med Unit, Atlanta, GA USA
[3] Off Hlth Promot & Dis Prevent, Grady Hlth Syst, Atlanta, GA USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 93卷 / 09期
关键词
D O I
10.1016/j.amjcard.2004.01.052
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective of this study was to determine the association between patient characteristics, specifically race, and the appropriate management of lipid-reducing therapy in patients with coronary heart disease (CHD) discharged from the hospital. Two hundred fifty-eight consecutive patients with diagnoses suggestive of CHD were identified in a large, inner-city university teaching hospital serving a predominantly indigent African American population. The outcome measure, suboptimal lipid management, evaluated the intensification of lipid-reducing therapy when indicated using the National Cholesterol Education Program guidelines for the low-density lipoprotein cholesterol goal. The overall rate of suboptimal lipid management was 48%. Black patients with CHD were significantly more likely to have suboptimal lipid management than nonblack patients by the time of hospital discharge (52.3% vs 16.7%, p = 0.021). The disparity in the clinical management of black patients with CHD may help explain the differential in health outcomes seen between black and white patients. (C) 2004 by Excerpta Medica, Inc.
引用
收藏
页码:1167 / 1170
页数:4
相关论文
共 50 条
  • [1] Race affects lipid-lowering management in hospitalized patients with coronary heart disease.
    Dressler, DD
    Byrapuneni, H
    Jacobson, T
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 : 172 - 173
  • [2] Intensive lipid-lowering therapy in patients with coronary heart disease
    Lauderdale, SA
    Sheehan, AH
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (02) : 329 - 334
  • [3] Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease
    Steffens, Daniel
    Bramlage, Peter
    Mueller, Julia
    Dorn, Cornelia
    Paar, W. Dieter
    Scheeff, Celine
    Kasner, Mario
    Rauch-Kroehnert, U.
    OPEN HEART, 2021, 8 (01):
  • [4] Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease
    Harnick, DJ
    Cohen, JL
    Schechter, CB
    Fuster, V
    Smith, DA
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (12): : 1416 - 1420
  • [5] Effects of age, sex, and race on lipid management in patients hospitalized with coronary artery disease
    Shah, R
    Rich, DS
    Rich, SE
    Rich, MW
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (08) : S113 - S113
  • [6] Lipid-lowering drugs and prevention of coronary heart disease.
    Chadarevian, R
    Bruckert, E
    Turpin, G
    ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE, 1997, 46 (02): : 89 - 98
  • [7] Lipid-lowering therapy for the primary prevention of coronary heart disease
    Gotto, AM
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (07) : 2078 - 2082
  • [8] Lipid-lowering strategies for the prevention of coronary heart disease: Reply
    Haq, IU
    Ramsay, LE
    Pickin, DM
    Yeo, WW
    Jackson, PR
    Payne, JN
    CLINICAL SCIENCE, 1997, 92 (04) : 431 - 432
  • [9] Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs
    Shepherd, J
    LANCET, 2002, 359 (9325): : 2271 - 2273
  • [10] Lipid-lowering and antiaggregatory efficacy of atorvastatin in coronary heart disease patients with combined hyperlipidemia
    Viigimaa, M
    Välkman, R
    ATHEROSCLEROSIS, 1999, 144 : 24 - 24